Thinking of joining a study?

Register your interest

NCT05871632 | NOT YET RECRUITING | Cardiomyopathies


The China CardioMyopathy Registry Study
Sponsor:

China National Center for Cardiovascular Diseases

Information provided by (Responsible Party):

Lei.Song,MD.&ph.D

Brief Summary:

Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, so it has a huge psychological and economic burden on family members. Studying the clinical characteristics of patients with cardiomyopathy is helpful for further diagnosis, treatment and management, which has important clinical and social significance.

Condition or disease

Cardiomyopathies

Detailed Description:

In this study, patients hospitalized with cardiomyopathy as the primary discharge diagnosis in China are recruited prospectively after informed consent was given. The investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hour Holter, echocardiography, MRI and other examinations if necessary. Data are collected with the use of case report forms (CRFs) and are entered into a web-based system. A 6 mL venous blood sample is obtained from consenting patients. Each participant is scheduled to be followed up by telephone every 12 months after admission to hospital.

Study Type : OBSERVATIONAL
Estimated Enrollment : 5000 participants
Official Title : The China CardioMyopathy Registry Study
Actual Study Start Date : 2023-07-01
Estimated Primary Completion Date : 2025-06-30
Estimated Study Completion Date : 2027-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 16 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.
Exclusion Criteria
  • * Patients who refuse to sign the informed consent or decline follow-up.

The China CardioMyopathy Registry Study

Location Details

NCT05871632


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

China, Beijing

Fuwai hospital

Beijing, Beijing, China, 100037

Loading...